Ziprasidone in Parkinson's Disease Psychosis
Dear Editor:
Hallucinations and delusions are frequent side effects of dopaminergic treatment in Parkinson's disease (PD) patients. These patients do not generally tolerate typical antipsychotic therapy with D 2 antagonist drugs. Ziprasidone is a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Clinical trials suggest that the drug is effective in treating schizophrenia (1) . We report remission of psychosis and improvement of motor symptoms in a PD patient taking ziprasidone.
Case Report
Mr A, a 70-year-old man with a 16-year history of PD, was admitted to our department for levodopa-induced psychosis. Antipsychotic treatment with clozapine had been effective but had to be discontinued owing to agranulocytosis. At admission, the patient was treated with L -DOPA/carbidopa 1200 mg, L -DOPA/benserazide 375 mg, entacapone 1200 mg, and quetiapine 800 mg daily. He had pronounced visual, auditory, and tactile hallucinations, as well as delusions of persecution. Physical examination showed hypomimia, stooped posture, and a slight resting tremor of the right hand. There were infrequent (< 1 daily) off-episodes, with akinesia and rigidity lasting up to 1.5 hours. Otherwise, activities of daily life were only moderately affected. The Uniform Parkinson Disease Rating Scale (UPDRS) score was 43/199. The results of laboratory tests and the findings on cranial magnetic resonance imaging, ECG, and EEG were unremarkable. L-DOPA/benserazide and quetiapine were discontinued without apparent effect. Aripiprazole 10 mg thrice daily was tried but revealed no benefit and had to be discontinued after 4 weeks, owing to motor side effects. At discontinuation, the UPDRS score was 101. Ziprasidone was initiated at 40 mg once daily and increased to 80 mg once daily over 3 days. Within 2 weeks, delusions and hallucinations subsided, and motor function improved fundamentally. Sitting, walking, dressing, showering, and eating without assistance became possible. On discharge, the UPDRS score was 42.
Ziprasidone is one of the newer atypical antipsychotic drugs; these drugs tend to cause fewer extrapyramidal side effects (EPSEs) than classic neuroleptics. Within the group, atypical neuroleptics have varying propensities to cause EPSEs. Clozapine appears to be superior in this regard and is widely recognized as a standard treatment for dopaminergic psychosis in PD. Experience with ziprasidone is lacking, and EPSE frequency has been estimated to equate that of olanzapine, which is not well tolerated in PD (2) . In our opinion, however, the choice of a neuroleptic drug in PD should depend on the probability of drug-induced Parkinson's symptoms and not of drug-induced dystonia, hyperkinesia, akathisia, and myoclonus-all of which are EPSEs. Two substances with the same overall EPSE frequency may not be equally safe in patients with PD. Akathisia has been reported with ziprasidone (3), and we have also encountered acute dystonia. However, Parkinson's symptoms occur rarely if at all, and therefore, ziprasidone may become a real alternative treatment for PD psychosis.
Combined Oral Venlafaxine and Intravenous Clomipramine-A: Successful Temporary Response in a Patient With Extremely Refractory Depression
We report a case of a married woman, aged 33 years, with treatment-refractory dependent and borderline personality disorder and major depression with atypical features, diagnosed according to DSM-IV criteria. She began to experience free-floating anxiety and incomplete panic attacks at age 26 years, which were soon followed by major depression. Two years later, at age 28 years, she presented to our outpatient clinic. She had already attempted suicide once by swallowing pills a couple of months prior to presenting. Her psychiatric family history was blank.
Given 1 mg dexamethasone, she was a nonsuppressor on the dexamethasone suppression test (DST) (based on the cut-off point of 5 µg/dL plasma cortisol) and had blunted response to 30 mg dexfenfluramine challenge test (cut-off 50 µU/L prolactin). Brain-imaging single photon emission computed tomography (SPECT) showed increased regional cerebral blood flow in the frontal lobes (+1.5 sd) and reduced regional cerebral blood flow (-0.3 to -1.4 sd) in the rest of brain areas.
The patient received the following adequate but unsuccessful treatment trials (including combinations) lasting at least 4 months each: 60 mg fluoxetine, 375 mg venlafaxine, 40 mg haloperidol, 6 mg risperidone, lithium (plasma levels 1.0 mEq/L), carbamazepine (plasma levels 9 µg/mL). She also had 8 clomipramine infusions (maximum 4 ampoules), with partial and unstable response for a couple of days. She refused ECT. During the last year, she has had rare mood-congruent auditory hallucinations.
We decided to try a more aggressive treatment with high dosages of intravenous (IV) clomipramine plus oral venlafaxine. The maximum dosage reached at day 15 was 6 ampoules IV clomipramine plus 225 mg oral venlafaxine.
On day 15, the patient responded with a dramatic remission of symptoms, almost to normothymic state. Her overall Hamilton Depression Rating Scale (HDRS) score decreased from 37 to 11, and her Hamilton Anxiety Rating Scale score decreased from 46 to 22. On the following HDRS indexes, her scores were as follows: depression symptoms decreased from 18 to 2; anxiety symptoms decreased from 8 to 6; insomnia symptoms decreased from 6 to 3; and nonspecific symptoms decreased from 5 to 0. This remission lasted for 37 days; then, obeying auditory hallucinations, the patient unsuccessfully attempted suicide by swallowing 30 tablets of diazepam 10 mg and thioridazine 30 mg. The mood change was acute, occurring within a few hours.
Clomipramine is not approved by the FDA for the treatment of depression; in continental Europe, however, it is considered the most effective agent, although there are only 5 published studies on its use to treat refractory depression (1) (2) (3) (4) (5) . Our report is the first one on the combined use of oral venlafaxine and clomipramine infusions. The only prior combined treatment reported concerns maprotiline.
The usual practice of infusions suggests starting with one-half ampoule of clomipramine and adding 1 ampoule every day to reach a maximum of 5 to 6 ampoules. Anecdotal data report higher dosages of 8 to 9 ampoules daily.
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Doxepin Increases Serum Cholesterol Levels
Doxepin is a well-known nonselective tricyclic antidepressant (TCA) that has been marketed in Germany for over 30 years and is still frequently applied. It causes common and group-specific side effects, including metabolic changes such as increases and decreases in blood sugar levels (1) . Other metabolic changes in patients treated with TCAs have occasionally been reported. For example, increased serum cholesterol in 24 patients treated with imipramine for panic disorder was observed (2) . Conversely, the same investigators also reported decreased high-density lipoprotein (HDL) cholesterol in patients on imipramine for panic disorder. Both depression patients and patients suffering from panic disorder showed an increase in the ratio of serum total cholesterol to HDL cholesterol under imipramine medication (3) . After an average of 7 months of nortriptyline treatment, 26 depression patients showed significantly elevated levels of triglycerides and very-low-density lipoproteins (VLDL); however, they did not show significant changes in cholesterol levels (4). Further, it has been shown that the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazapine increases serum cholesterol to over 20% above the upper limit of normal in approximately 15% of patients (1) .
We describe a patient who showed a significant isolated elevation of serum cholesterol while on monotherapy with doxepin.
Case Report
A 32-year-old white woman suffering from severe recurrent depression without psychotic symptoms, diagnosed according to ICD-10 criteria, had been on venlafaxine for 20 weeks, with serum cholesterol levels within the normal range (is 201 to 221 mg/dL). She switched from venlafaxine to doxepin, and by week 21, her cholesterol rose to 271 mg/dL. In week 25, her cholesterol reached a maximum level around 320 mg/dL, which persisted for 20 more days. After she stopped taking doxepin and switched to reboxetine in week 27, her serum cholesterol gradually fell within 3 weeks from 312 mg/dL to 209 mg/dL. During this time, reboxetine was given as an antidepressant. Throughout the entire period, triglyceride levels were within the normal range.
Discussion
At present, there are limited and contradictory data with respect to changes in cholesterol levels in patients on antidepressant medications. Apart from limited data on TCAs, there are also reports on the effects of other antidepressants on lipid metabolism. A prospective study described a cholesterol-lowering effect
